Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer
http://www.clinicaltrials.gov/ct2/sh...m=her2&rank=69
Official Title: The Feasibility of Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer Sponsor: Memorial Sloan-Kettering Cancer Center NY The primary objective of this trial is to determine the feasibility of this regimen in patients with node-negative HER-2/neu overexpressed /amplified breast cancer with a tumor size of < 3 cm. The regimen is considered feasible if patients are able to complete the paclitaxel, trastuzumab, and lapatinib (THL) portion of the regimen without a dose delay or reduction or grade 3 or greater QTc prolongation. |
All times are GMT -7. The time now is 05:51 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021